Maëlle Duffey

Maëlle Duffey


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2021 in Trends in Parasitology
Verified
Journal Article
Open access
MDMaëlle Duffey
Maëlle Duffey
BBBenjamin Blasco
Benjamin Blasco
JBJeremy N. Burrows
Jeremy N. Burrows
TWTimothy N. C Wells
Timothy N. C Wells
DFDavid A. Fidock
David A. Fidock
DLDidier Leroy
Didier Leroy
Strategies to counteract or prevent emerging drug resistance are crucial for the design of next-generation antimalarials. In the past, resistant parasites were generally identified following treatment failures in patients, and compounds would have to be abandoned late in development. An early understanding of how candidate therapeutics lose efficacy as parasites evolve resistance is important to facilitate drug design and improve resistance detection and monitoring up to the postregistration phase. We describe a new strategy to assess resistance to antimalarial compounds as early as possible in preclinical development by leveraging tools to define the Plasmodium falciparum resistome, predict potential resistance risks of clinical failure for candidate therapeutics, and inform decisions to guide antimalarial drug development.

13 October 2023 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
UTUrsula Theuretzbacher
Ursula Theuretzbacher
BBBenjamin Blasco
Benjamin Blasco
MDMaëlle Duffey
Maëlle Duffey
LPLaura Piddock
Laura Piddock

25 April 2024 in ACS Infectious Diseases
Verified
Journal Article
Open access
MDMaëlle Duffey
Maëlle Duffey
RJRavindra P. Jumde
Ravindra P. Jumde
RCRenata M.A. da Costa
Renata M.A. da Costa
HRHenni-Karoliina Ropponen
Henni-Karoliina Ropponen
BBBenjamin Blasco
Benjamin Blasco
LPLaura Piddock
Laura Piddock
Efflux is a natural process found in all prokaryotic and eukaryotic cells that removes a diverse range of substrates from inside to outside. Many antibiotics are substrates of bacterial efflux pumps, and modifications to the structure or overexpression of efflux pumps are an important resistance mechanism utilized by many multidrug-resistant bacteria. Therefore, chemical inhibition of bacterial efflux to revitalize existing antibiotics has been considered a promising approach for antimicrobial chemotherapy over two decades, and various strategies have been employed. In this review, we provide an overview of bacterial multidrug resistance (MDR) efflux pumps, of which the resistance nodulation division (RND) efflux pumps are considered the most clinically relevant in Gram-negative bacteria, and describe over 50 efflux inhibitors that target such systems. Although numerous efflux inhibitors have been identified to date, none have progressed into clinical use because of formulation, toxicity, and pharmacokinetic issues or a narrow spectrum of inhibition. For these reasons, the development of efflux inhibitors has been considered a difficult and complex area of research, and few active preclinical studies on efflux inhibitors are in progress. However, recently developed tools, including but not limited to computational tools including molecular docking models, offer hope that further research on efflux inhibitors can be a platform for research and development of new bacterial efflux inhibitors.

15 May 2024 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
MDMaëlle Duffey
Maëlle Duffey
Robert W ShaferRobert W Shafer
Robert W Shafer
JTJuliano Timm
Juliano Timm
JBJeremy N. Burrows
Jeremy N. Burrows
NFNader Fotouhi
Nader Fotouhi
DLDidier Leroy
Didier Leroy

23 January 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AWAnnabelle Walz
Annabelle Walz
MDMaëlle Duffey
Maëlle Duffey
GAGhaith Aljayyoussi
Ghaith Aljayyoussi
SSSibylle Sax
Sibylle Sax
DLDidier Leroy
Didier Leroy
SWSergio Wittlin
Sergio Wittlin
With artemisinin-resistant Plasmodium falciparum parasites emerging in Africa, the need for new antimalarial chemotypes is persistently high. The ideal pharmacodynamic parameters of a candidate drug are a rapid onset of action and a fast rate of parasite killing or clearance. To determine these parameters, it is essential to discriminate viable from nonviable parasites, which is complicated by the fact that viable parasites can be metabolically inactive, whilst dying parasites can still be metabolically active and morphologically unaffected. Standard growth inhibition assays, read out via microscopy or [3H] hypoxanthine incorporation, cannot reliably discriminate between viable and nonviable parasites. Conversely, the in vitro parasite reduction ratio (PRR) assay is able to measure viable parasites with high sensitivity. It provides valuable pharmacodynamic parameters, such as PRR, 99.9% parasite clearance time (PCT99.9%) and lag phase. Here we report the development of the PRR assay version 2 (V2), which comes with a shorter assay duration, optimized quality controls and an objective, automated analysis pipeline that systematically estimates PRR, PCT99.9% and lag time and returns meaningful secondary parameters such as the maximal killing rate of a drug (Emax) at the assayed concentration. These parameters can be fed directly into pharmacokinetic/pharmacodynamic models, hence aiding and standardizing lead selection, optimization, and dose prediction.

21 July 2022 in SLAS Discovery
Verified
Journal Article
Open access
KDKoen J. Dechering
Koen J. Dechering
MTMartijn Timmerman
Martijn Timmerman
KRKim Rensen
Kim Rensen
KKKarin M.J. Koolen
Karin M.J. Koolen
SHSaman Honarnejad
Saman Honarnejad
MDMaëlle Duffey
Maëlle Duffey
A central challenge of antimalarial therapy is the emergence of resistance to the components of artemisinin-based combination therapies (ACTs) and the urgent need for new drugs acting through novel mechanism of action. Over the last decade, compounds identified in phenotypic high throughput screens (HTS) have provided the starting point for six candidate drugs currently in the Medicines for Malaria Venture (MMV) clinical development portfolio. However, the published screening data which provided much of the new chemical matter for malaria drug discovery projects have been extensively mined. Here we present a new screening and selection cascade for generation of hit compounds active against the blood stage of Plasmodium falciparum. In addition, we validate our approach by testing a library of 141,786 compounds not reported earlier as being tested against malaria. The Hit Generation Library 1 (HGL1) was designed to maximise the chemical diversity and novelty of compounds with physicochemical properties associated with potential for further development. A robust HTS cascade containing orthogonal efficacy and cytotoxicity assays, including a newly developed and validated nanoluciferase-based assay was used to profile the compounds. 75 compounds (Screening Active hit rate of 0.05%) were identified meeting our stringent selection criteria of potency in drug sensitive (NF54) and drug resistant (Dd2) parasite strains (IC50 ≤ 2 µM), rapid speed of action and cell viability in HepG2 cells (IC50 ≥ 10 µM). Following further profiling, 33 compounds were identified that meet the MMV Confirmed Active profile and are high quality starting points for new antimalarial drug discovery projects.